Tysabri and PML: What Massachusetts Patients Should Know About Symptoms and Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding the timeline for PML onset is critical. The medical community has long emphasized the importance of informed decision-making when it comes to biologic therapies. This page provides a factual overview of PML symptoms, risk factors, and what to document in your medical records.

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic medication approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the condition has been documented in patients receiving Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients on Tysabri for any new sign or symptom suggestive of PML and to withhold dosing immediately at the first such sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Adverse Event Data

The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. In the FDA Adverse Event Reporting System (FAERS), adverse events most frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the spectrum of neurological symptoms that may overlap with PML or other complications. For patients in Massachusetts who have developed PML after Tysabri exposure, legal considerations involve the statute of limitations for filing a claim. In Massachusetts, the statute of limitations for personal injury actions, including product liability claims, is generally three years from the date the injury is discovered or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can be variable. The risk increases with treatment duration beyond two years, but PML can occur at any point during therapy. The latency period between initial Tysabri infusion and onset of PML symptoms may range from months to several years, complicating the determination of when the injury was discoverable.

Legal Implications and Statute of Limitations in Massachusetts

Adequacy of warnings is a central issue in such claims. The Tysabri label includes a boxed warning about PML risk and identifies specific risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, the need for vigilant monitoring, and the importance of early discontinuation at the first sign of PML. The label states that physicians should consider whether the expected benefit is sufficient to offset the PML risk when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient developed PML without having been informed of these risks or without appropriate monitoring, the adequacy of the warning may be contested. For affected patients and their families, consulting with an attorney experienced in pharmaceutical litigation is advisable to assess the specific facts of the case, including the timing of Tysabri use, the onset of PML symptoms, and the date of diagnosis. The statute of limitations in Massachusetts requires prompt action after discovery of the injury. Given the severe and often fatal nature of PML, timely legal evaluation is critical to preserve the right to seek compensation for medical expenses, lost income, and pain and suffering.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury actions, including product liability claims, is generally three years from the date the injury is discovered or reasonably should have been discovered. For PML, the latency period between Tysabri exposure and symptom onset can vary, so it is important to consult an attorney promptly after diagnosis.

What are the risk factors for developing PML while on Tysabri?

Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.

What symptoms should Tysabri patients watch for that may indicate PML?

Symptoms of PML include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. Patients should report any new or worsening symptoms to their healthcare provider immediately.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.